ストックスクリーナーアプリを入手
3.96
3.66%
0.14
アフターアワーズ：
3.96
前日終値:
$3.82
開ける：
$3.87
24時間の取引高:
768.44K
Relative Volume:
1.14
時価総額：
$185.88M
収益：
$138.90M
当期純損益:
$-107.15M
株価収益率:
-1.5694
EPS:
-2.5232
ネットキャッシュフロー:
$-79.85M
1週間 パフォーマンス:
-12.39%
1か月 パフォーマンス:
-37.04%
6か月 パフォーマンス:
-24.71%
1年 パフォーマンス:
-43.59%
1日の値動き範囲:
$3.87
$4.127
1週間の範囲:
$3.64
$4.555
52週間の値動き範囲:
$3.64
$8.77
Quanterix Corp Stock (QTRX) Company Profile
Compare QTRX vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
QTRX
Quanterix Corp
|
3.96 | 179.31M | 138.90M | -107.15M | -79.85M | -2.5232 |
ABT
Abbott Laboratories
|
104.83 | 180.82B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
327.65 | 125.72B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
87.89 | 111.16B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
69.78 | 101.28B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
82.67 | 47.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Quanterix Corp Stock (QTRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-11 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2024-02-01 | 開始されました | Scotiabank | Sector Outperform |
| 2023-09-25 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-08 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-05-23 | アップグレード | Goldman | Neutral → Buy |
| 2022-08-15 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2022-08-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2022-08-09 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-03-02 | アップグレード | Goldman | Sell → Neutral |
| 2021-10-15 | 再開されました | Cowen | Outperform |
| 2021-06-04 | 開始されました | Goldman | Sell |
すべてを表示
Quanterix Corp (QTRX) 最新ニュース
Quanterix (QTRX) CLO Daniel Char granted RSUs and stock options - Stock Titan
Quanterix (QTRX) COO gains shares from RSU vesting as stock withheld for taxes - Stock Titan
Quanterix (QTRX) COO Miller details PSUs, RSUs, options and shares in Form 3 - Stock Titan
Quanterix (QTRX) CFO nets common shares from RSU vesting and tax withholding - Stock Titan
Invenomic Capital Management LP Grows Stake in Quanterix Corporation $QTRX - MarketBeat
Risk Report: Whats the MACD signal for Quanterix CorporationRate Cut & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Quanterix rises on CMS price for LucentAD Alzheimer blood biomarker test - MSN
Quanterix at Leerink Global Healthcare Conference: Strategic Growth Insights By Investing.com - Investing.com Canada
Quanterix at Leerink Global Healthcare Conference: Strategic Growth Insights - Investing.com
Quanterix at TD Cowen Conference: Strategic Growth and Diagnostics Focus - Investing.com
William Blair Investment Management LLC Increases Holdings in Quanterix Corporation $QTRX - MarketBeat
Quanterix Corporation (NASDAQ:QTRX) Q4 2025 Earnings Call Transcript - Insider Monkey
Quanterix Q4 Earnings Call Highlights - Defense World
Quanterix (QTRX) Revenue Growth Keeps Losses Central To Bulls’ Long-Term Narrative - simplywall.st
Quanterix (QTRX) Q4 2025 Earnings Call Transcript - AOL.com
Quanterix Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Quanterix Q4 2025 shows revenue beat but EPS miss - Investing.com Australia
Earnings call transcript: Quanterix Q4 2025 shows revenue beat but EPS miss By Investing.com - Investing.com South Africa
Quanterix Corp (QTRX) Q4 2025 Earnings Call Highlights: Revenue Surge Amidst Strategic Shifts - GuruFocus
Quanterix Q4 2025 Earnings Call Transcript - MarketBeat
Quanterix Q4 2025 slides: cost cuts drive path to cash flow breakeven - Investing.com South Africa
Quanterix Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Quanterix earnings missed by $0.06, revenue topped estimates - Investing.com Canada
Quanterix Corporation (QTRX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Quanterix (QTRX) Releases Revenue and Margin Projections for 202 - GuruFocus
Quanterix Corporation (QTRX) Releases Q4 2025 Earnings: Revenue Beats but EPS Slightly Misses - Quiver Quantitative
Quanterix (NASDAQ:QTRX) Releases Earnings Results, Misses Expectations By $0.11 EPS - MarketBeat
Quanterix Corporation 8-K Filing Analysis - TradingView
Quanterix (QTRX) grows Q4 revenue, deepens 2025 loss, eyes 2026 cash breakeven - Stock Titan
Quanterix Earnings Report: Q4 Overview - Benzinga
Alzheimer’s blood test heads to 15,000 community events a year - Stock Titan
Quanterix (QTRX) Set to Announce Q4 Earnings with Revenue Growth Expected - GuruFocus
Quanterix (QTRX) to Release Earnings on Monday - Defense World
Quanterix Corp expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Earnings Outlook For Quanterix - Benzinga
Quanterix Corp (QTRX) Q4 2025 Earnings Report Preview: What To L - GuruFocus
Quanterix to Participate in Upcoming Investor Conferences - ChartMill
Envestnet Asset Management Inc. Grows Holdings in Quanterix Corporation $QTRX - Defense World
Biomarker firm Quanterix plans two March investor webcasts - Stock Titan
QTRX Should I Buy - Intellectia AI
Quanterix (QTRX) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Investors can hear Quanterix 2025 results discussed on Mar. 2 call - Stock Titan
Quanterix (NASDAQ:QTRX) Shares Up 0.7%Time to Buy? - MarketBeat
Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer’s Blood Test - Clinical Lab Products
With 68% ownership, Quanterix Corporation (NASDAQ:QTRX) boasts of strong institutional backing - Yahoo Finance
Quanterix submits FDA 510(k) for multi-analyte Alzheimer's blood test - MSN
Aug Swings: Should value investors consider Quanterix CorporationGlobal Markets & Growth Focused Entry Point Reports - baoquankhu1.vn
Quanterix Submits FDA 510(k) for Multi-Analyte Alzheimer's Blood Test - TradingView
Quanterix (QTRX) Submits Alzheimer's Blood Test for FDA Approval - GuruFocus
Quanterix submits FDA 510(k) for multi-analyte Alzheimer’s blood test - Investing.com
Blood test to spot Alzheimer’s earlier moves to FDA review - Stock Titan
Quanterix Corp (QTRX) 財務データ
収益
当期純利益
現金流量
EPS
1.53%
大文字化:
|
ボリューム (24 時間):